Otros idiomas MEI Pharma, Inc. London S.E.

Acciones

0JW9

US55279B3015

Mercado cerrado - London S.E. Otros sitios de cotización 15:35:44 01/03/2023			Varia. Cinco días.	Varia. 1 de enero.
4,336 ^USD	-91,91 %		+53,49 %	-25,50 %

09/05	MEI Pharma, Inc. informa de los resultados del tercer trimestre y de los nueve meses finalizados el 31 de marzo de 2024	CI
11/04	MEI Pharma, Inc. anuncia un plan estratégico para aprovechar los recientes datos clínicos positivos de voruciclib y ME-344	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	14/05
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights	09/05
MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	09/05
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab in Relapsed Metastatic Colorectal Cancer Patients	12/04
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	11/04
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344	11/04
MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	11/04
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	11/04
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum	10/04
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	26/03
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	26/03
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	15/02
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights	13/02
MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13/02
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024	16/01
MEI Pharma : Change in Certifying Accountants - Form 8-K	26/12
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	14/12
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023	11/12
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023	11/12
Earnings Flash (MEIP) MEI PHARMA Posts Q1 Revenue $65.3M	09/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas MEI Pharma, Inc. London S.E.

Acciones

0JW9

US55279B3015

Otros idiomas

Filtros